Article
Performance evaluation of a fully closed real-time PCR platform for the detection of KRAS p.G12C mutations in liquid biopsy of patients with non-small cell lung cancer.
Journal of clinical pathology - 1 May 2022
Gragnano Gianluca, Nacchio Mariantonia, Sgariglia Roberta, Conticelli Floriana, Iaccarino Antonino, De Luca Caterina, Troncone Giancarlo, Malapelle Umberto
Abstract excerpt
Whenever tissue sample is not available, non-small cell lung cancer (NSCLC) biomarker testing is performed with liquid biopsy. The Kirsten rat sarcoma viral oncogene homolog (KRAS) p.G12C mutation is a novel target in patients with NSCLC. In this study, 33 NSCLC frozen plasma samples, previously characterised for KRAS mutational status by next generation sequencing (NGS), were processed by the fully automated...
Topics
- Carcinoma, Non-Small-Cell Lung
- Cell-Free Nucleic Acids
- DNA Mutational Analysis
- Humans
- Liquid Biopsy
- Lung Neoplasms
- Mutation
- Proto-Oncogene Proteins p21(ras)
- Real-Time Polymerase Chain Reaction